In our earlier investigations, we demonstrated that miR-206 has the capacity to improve hepatic insulin resistance, promote glycolysis, and inhibit gluconeogenesis by targeting Ptpn1 (protein tyrosine phosphatase non-receptor type 1). The gene discussed is PTPN1; the disease is Insulin resistance.